480 Biomedical Announces Initial Observations From OCT Sub-Study of the STANCE Trial Evaluating the First Self-Expanding Bioresorbable Scaffold for Superficial Femoral Artery Disease

WATERTOWN, Mass.--(BUSINESS WIRE)--480 Biomedical announced today that the first twenty-five patients enrolled in its STANCE trial have been successfully implanted with the company’s fully self-expanding, bioresorbable scaffold. Dr. Andrew Holden presented data highlighting the STANCE trial’s pioneering use of Optical Coherence Tomography (OCT) to prospectively evaluate the performance of 480 Biomedical’s Stanza™ SFA scaffold. The presentation was delivered at the Late-Breaking Clinical Trials session of the 10th Annual Vascular InterVentional Advances (VIVA) Meeting.